iShares NASDAQ Biotechnology Index (ETF) Draws Bullish Options Activity Today

 iShares NASDAQ Biotechnology Index (ETF) Draws Bullish Options Activity Today

In today’s session iShares NASDAQ Biotechnology Index (ETF) (IBB) registered an unusually high (816) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious IBB increase. With 816 contracts traded and 454 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: IBB161118C00272500 closed last at: $1.8 or 5.3% down. About 593,211 shares traded hands. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has declined 6.65% since April 5, 2016 and is downtrending. It has underperformed by 8.61% the S&P500.

iShares Nasdaq Biotechnology ETF , formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The ETF has a market cap of $7.41 billion. The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). It has a 2.9 P/E ratio. The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

IBB Company Profile

iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, and which also meet other eligibility criteria. The Index is one of the eight sub-indices of the NASDAQ Composite, which measures all common stocks listed on The NASDAQ Stock Market, Inc.

More notable recent iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) news were published by: Fool.com which released: “2 Reasons Why the iShares NASDAQ Biotechnology Index (ETF) Tumbled 11% in October” on November 07, 2016, also Investorplace.com with their article: “The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Critical Level” published on October 17, 2016, Profitconfidential.com published: “iShares NASDAQ Biotechnology ETF: Has IBB Stock Finally Bottomed?” on July 17, 2016. More interesting news about iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) were released by: Etfdailynews.com and their article: “BlackRock: Health Care Sector Sell-Off Overdone” published on October 20, 2016 as well as Etfdailynews.com‘s news article titled: “Biotech ETF Testing Critical Support Levels” with publication date: October 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment